The 2010 McDonald criteria for the diagnosis of multiple sclerosis are widely used in research
and clinical practice. Scientific advances in the past 7 years suggest that they might no …

… G. Comi has received compensation for consulting services and/or speaking activities
from Novartis, Teva, Sanofi, Genzyme, Merck Serono, Biogen, Bayer, Serono Symposia …

In the past 20 years the treatment scenario of multiple sclerosis has radically changed. The
increasing availability of effective disease-modifying therapies has shifted the aim of …

Background Interferon beta reduces activity in multiple sclerosis as measured clinically and
by magnetic resonance imaging (MRI). We assessed the effect of interferon beta-1a on the …

Background Glatiramer acetate, approved for the treatment of relapsing-remitting multiple
sclerosis, reduces relapses and disease activity and burden monitored by MRI. We assessed …

… with relapsing multiple sclerosis - Comi - 2001 - Annals of Neurology - Wiley Online Library
… Relapses could be treated with a standard dose of 1.0 g intravenous methylprednisolone for …

Background Cladribine provides immunomodulation through selective targeting of lymphocyte
subtypes. We report the results of a 96-week phase 3 trial of a short-course oral tablet …

Background Fingolimod (FTY720), a sphingosine-1-phosphate–receptor modulator that
prevents lymphocyte egress from lymph nodes, showed clinical efficacy and improvement on …

Background Two proof-of-concept clinical trials have provided evidence that laquinimod
reduces disease activity in patients with relapsing–remitting multiple sclerosis. Methods We …

Background B cells influence the pathogenesis of multiple sclerosis. Ocrelizumab is a humanized
monoclonal antibody that selectively depletes CD20+ B cells. Methods In two identical …